KR20160059152A - Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component - Google Patents
Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component Download PDFInfo
- Publication number
- KR20160059152A KR20160059152A KR1020140160646A KR20140160646A KR20160059152A KR 20160059152 A KR20160059152 A KR 20160059152A KR 1020140160646 A KR1020140160646 A KR 1020140160646A KR 20140160646 A KR20140160646 A KR 20140160646A KR 20160059152 A KR20160059152 A KR 20160059152A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- obesity
- extract
- present
- thistle
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 239000000284 extract Substances 0.000 title claims abstract description 36
- 230000003579 anti-obesity Effects 0.000 title claims abstract description 12
- 241000729173 Cirsium japonicum Species 0.000 title claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 241000132536 Cirsium Species 0.000 claims description 29
- 208000008589 Obesity Diseases 0.000 claims description 24
- 235000020824 obesity Nutrition 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 235000019197 fats Nutrition 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 238000010171 animal model Methods 0.000 description 11
- 235000013305 food Nutrition 0.000 description 10
- 235000013361 beverage Nutrition 0.000 description 7
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 6
- 229940117893 apigenin Drugs 0.000 description 6
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 6
- 235000008714 apigenin Nutrition 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000001596 intra-abdominal fat Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- -1 body heat generators Substances 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002830 appetite depressant Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037237 body shape Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000006052 feed supplement Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 101100168093 Caenorhabditis elegans cogc-2 gene Proteins 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100221487 Mus musculus Cog2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241001593968 Vitis palmata Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 엉겅퀴(Cirsium japonicum) 잎 열수 추출물을 유효성분으로 함유하는 항비만용 조성물, 상기 조성물을 함유하는 비만 치료 또는 예방용 약학조성물 및 건강기능식품에 관한 것이다.The present invention relates to an anti-obesity composition containing an extract of Cirsium japonicum leaf as an active ingredient, a pharmaceutical composition for treating or preventing obesity containing the composition, and a health functional food.
최근 경제의 현대화에 따른 생활 수준의 향상으로 지방과 당분의 섭취는 늘고 섬유질의 섭취는 줄어드는 새로운 식사 문화, 특히 외식 문화의 정착으로 고단백 위주의 식단 선호 현상이 두드러지고 있으며, 이에 반하여 육체적인 활동이 거의 없는 현대인의 생활 습관으로 비만 인구가 급속히 늘고 있는 것이 현실이다. 고열량 식품의 섭취가 증가하고 섬유질 섭취가 줄어들면서 비만, 특히 복부비만이 사회적으로 심각한 문제로 떠오르고 있는 것이다. 비만은 지방조직이 과잉 증가한 상태를 말하며 비만에 의한 체중의 증가는 대부분 지방의 증가에 기인하는 것이다.In recent years, the modernization of the economy has led to a rise in the level of living standards, which leads to an increase in the intake of fat and sugar and a decrease in the consumption of fiber. In particular, It is a reality that the obesity population is rapidly increasing due to the lifestyle of modern people who hardly exist. Obesity, especially abdominal obesity, is emerging as a serious social problem as the intake of high calorie foods increases and the intake of fiber decreases. Obesity refers to the state of overgrowth of fat tissue, and the increase in body weight due to obesity is mostly due to the increase in fat.
비만의 유해성은 비만 그 자체로 지방조직에 의한 복부의 압박으로 인하여 변비와 소화불량, 위장장해 등을 일으키는 경우가 많을 뿐만 아니라, 이로 인해 많은 성인병들의 위험요소가 된다는데 문제가 있다. 비만은 암을 비롯한 동맥경화, 심장병, 고혈압, 당뇨병 등과 같은 성인병과 합병증을 일으키는 등 만병의 근원이라고 알려져 있으며 1996년 세계보건기구(WHO)도 비만은 치료가 필요한 병이라고 경고한 바 있다. 75만 명을 대상으로 한 연구에 의하면 평균 체중보다 40% 이상인 남성과 여성에서 정상 체중인 사람들보다 사망률이 1.9배 증가된 것으로 조사되었다.The hazard of obesity is that obesity itself causes constipation, indigestion and gastrointestinal disturbance due to the pressure of abdomen caused by adipose tissue, which is a risk factor for many adult diseases. Obesity is known to be the source of all diseases including cancer, arteriosclerosis, heart disease, hypertension, diabetes, and other diseases and complications. In 1996, the World Health Organization (WHO) warned that obesity is a disease that requires treatment. A study of 750,000 people found that men and women over 40% of their average body weight had a 1.9-fold increase in mortality rates compared to those of normal weight.
비만은 신체에 지방이 과잉되게 축적된 상태이며, 지방이 체내에 축적되는 원인은 당질(탄수화물)의 과잉섭취 또는 지방을 과잉섭취하는 데 있다. 비만에 달하는 메카니즘은 당질을 과잉 섭취함으로써 음식물 중에 함유되어있는 당질이 소화되어 단당이 되고 소장을 통해 체내로 흡수되며, 혈당이 상승하여 그 자극으로 분비되는 인슐린이 지방세포에 작용해서 혈액 중의 단당을 지방세포가 받아들이게 되어 지방으로 바꾸는 것이다. 또한 식품성분 중 가장 고칼로리인 지방(트리글리세리드)은 췌장 리파아제에 의해 분해되어 소장을 통해 흡수되며, 섭취 칼로리의 과잉으로 저장 칼로리가 증가되는 결과가 된다. 즉, 과잉 지방섭취에 의해 비만이 되는 것이다.Obesity is an accumulation of excess fat in the body, and the cause of accumulation of fat in the body is excessive intake of carbohydrates (carbohydrates) or excessive intake of fat. The mechanism that reaches obesity is that the sugar contained in the food is digested and becomes monosaccharide, absorbed into the body through the small intestine, and the blood sugar is elevated and insulin secreted by the stimulus acts on the adipocyte so that monosaccharide Fat cells will be accepted and converted to fat. In addition, the highest calorie fat (triglycerides) in food is decomposed by pancreatic lipase and absorbed through the small intestine, resulting in an increase in stored calories due to excessive intake of calories. That is, obesity is caused by excessive fat intake.
현재 비만증 치료제로서 식욕 억제제, 체열 발생제, 이뇨제 등이 사용되고 있으며 이 중 가장 많이 사용되는 비만 치료제는 식욕 억제제로서 미국에서 한 해 10천만 불의 시장을 형성하고 있다. 그러나 비만 치료용 식욕 억제제는 혈압 상승, 의존성, 설사, 변비, 불면, 불안 등의 부작용을 나타내므로 비만증을 억제하기 위하여 오랜 세월 동안 안전성과 생리기능이 검증된 여러 식품소재의 이용에 대한 관심이 높아지고 있다. 현재 비만인을 위한 건강식품으로 식이섬유, 생약재 및 여러 식품소재를 함유하는 제품들이 개발되어 있으나, 식사량을 줄이고 이 제품들을 섭취할 경우 여러 영양소의 부족으로 인한 부작용으로 정상적인 생활이 어렵고, 복용을 중단하면 빠르게 다시 비만해지는 것으로 알려져 있다.Currently, appetite suppressants, body heat generators, diuretics, etc. are being used as anti-obesity drugs, and the most used obesity drugs are the appetite suppressants in the United States, forming a market of $ 10 million a year. However, since appetite suppressants for obesity treatments exhibit side effects such as elevated blood pressure, dependence, diarrhea, constipation, insomnia, and anxiety, there is a growing interest in using various food materials that have been proven for safety and physiological function for many years have. Currently, dietary fiber, herbal medicines, and various food products have been developed for obese people. However, when eating these foods, it is difficult to live a normal life due to the lack of nutrients due to lack of nutrients. It is known to quickly become obese again.
엉겅퀴(Cirsium japonicum var. ussuriense)는 국화과(Compositae)에 속하는 다년생 초본으로 한방에서 지상부 또는 지하부(뿌리)를 대계라하여 약용으로 활용해왔다. 잎, 줄기, 꽃과 씨 등 지상부는 개화시기에서 씨가 여무는 5~6월에 채취하고, 뿌리는 가을에 채취하여 건조시킨 후 열수 또는 알콜 추출에 의한 약성분을 토혈, 혈뇨, 대하, 간염 및 고혈압 등 치료에 활용해왔다.Thistle ( Cirsium japonicum var. Ussuriense ) is a perennial herb that belongs to the Compositae family, and has been used as a medicinal herb, either on the ground or under the ground (root). Leaves, stems, flowers and seeds are collected from May to June when the seeds are bloomed at the flowering season, and the roots are picked and dried in the autumn, and the herbaceous substances by hot water or alcohol extraction are collected from blood, hematuria, And hypertension.
한국공개특허 제2012-0003693호에는 적포도 추출물, 녹차 추출물, 대두 추출물 및 L-카르니틴을 유효성분으로 함유하는 항비만 조성물이 개시되어 있고, 한국등록특허 제1177379호에는 산사 추출물, 율무 추출물, 청고추 추출물 및 팥싹 추출물을 함유하는 항비만용 조성물이 개시되어 있으나, 본 발명의 엉겅퀴 잎 추출물을 유효성분으로 함유하는 항비만 조성물과는 상이하다.Korean Patent Publication No. 2012-0003693 discloses an anti-obesity composition containing red grape extract, green tea extract, soybean extract and L-carnitine as an active ingredient. In Korean Patent No. 1177379, An extract of pepper and an extract of bean sprouts is disclosed. However, this composition is different from the anti-obesity composition containing the thistle leaf extract of the present invention as an active ingredient.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명은 엉겅퀴 잎 열수 추출물을 유효성분으로 함유함으로써, 비만 억제 효과가 우수한 항비만 조성물을 제공하는 데 그 목적이 있다.It is an object of the present invention to provide an anti-obesity composition which is excellent in an obesity-suppressing effect by containing thistle leaf hot-water extract as an effective ingredient.
상기 과제를 해결하기 위해, 본 발명은 엉겅퀴(Cirsium japonicum) 잎 열수 추출물을 유효성분으로 함유하는 항비만용 조성물을 제공한다.In order to solve the above problems, the present invention thistle (Cirsium The present invention provides a composition for anti-obesity containing as an active ingredient a hot-water extract of japonicum leaf.
또한, 본 발명은 상기 조성물을 함유하는 비만 치료 또는 예방용 약학조성물을 제공한다.The present invention also provides a pharmaceutical composition for the treatment or prevention of obesity containing the above composition.
또한, 본 발명은 상기 조성물을 함유하는 비만 예방 또는 개선용 건강기능식품을 제공한다.In addition, the present invention provides a health functional food for preventing or improving obesity containing the composition.
본 발명의 엉겅퀴(Cirsium japonicum) 잎 열수 추출물을 유효성분으로 함유하는 조성물은 체중 및 내장지방 감소와 더불어 혈중 중성지방 및 콜레스테롤 함량을 감소시켜 비만 억제 효과가 우수하여 비만 억제를 위한 의약품 및 식품산업상 매우 유용한 발명이 될 것이다.The composition containing the hydrothermal extract of Cirsium japonicum leaf as an active ingredient of the present invention is effective in reducing weight and visceral fat and reducing triglyceride and cholesterol content in the blood, It will be a very useful invention.
도 1은 엉겅퀴 추출물 투여에 따른 실험동물의 체형 변화를 보여준다.
도 2는 엉겅퀴 추출물 투여에 따른 실험동물의 내장지방 변화를 보여준다.
도 3은 엉겅퀴 추출물 투여에 따른 실험동물의 혈중 중성지방 함량을 비교한 그래프이다.
도 4는 엉겅퀴 추출물 투여에 따른 실험동물의 혈중 콜레스테롤 함량을 비교한 그래프이다.
도 5는 엉겅퀴 추출물 투여에 따른 실험동물의 혈중 HDL 함량을 비교한 그래프이다.
도 6은 엉겅퀴 추출물 투여에 따른 실험동물의 혈중 LDL 함량을 비교한 그래프이다.
도 1 내지 6의 정상대조군(Normal control): 일반고형사료 급여군, 대조군(Control): 고지방사료 급여군, CLE: 고지방사료 급여 + 엉겅퀴 추출물 투여군, Apigenin: 고지방사료 급여 + 아피게닌 투여군을 의미한다.FIG. 1 shows changes in body shape of experimental animals according to administration of thistle extract.
FIG. 2 shows visceral fat changes in experimental animals according to administration of thistle extract.
FIG. 3 is a graph comparing the blood triglyceride contents of experimental animals with thistle extract administration.
FIG. 4 is a graph comparing the blood cholesterol content of experimental animals with administration of thistle extract. FIG.
FIG. 5 is a graph comparing HDL contents in blood of experimental animals according to administration of thistle extract. FIG.
FIG. 6 is a graph comparing blood LDL contents of experimental animals according to administration of thistle extract. FIG.
Normal control in FIGS. 1 to 6 indicates the general solid feed group, control (control): high fat feed group, CLE: high fat feed supplement + thistle extract administration group, Apigenin: high fat feed supplement + apigenin administration group .
본 발명의 목적을 달성하기 위하여, 본 발명은 엉겅퀴(Cirsium japonicum) 잎 열수 추출물을 유효성분으로 함유하는 항비만용 조성물을 제공한다.In order to accomplish the object of the present invention, the present invention provides an anti-obesity composition containing a hydrothermal extract of Cirsium japonicum leaf as an active ingredient.
본 발명의 항비만용 조성물에서, 상기 엉겅퀴 잎 추출물은 바람직하게는 건조된 엉겅퀴 잎에 물을 첨가한 후 80~120℃에서 2~4시간 동안 열수 추출하여 제조된 추출물일 수 있으며, 더욱 바람직하게는 건조된 엉겅퀴 잎에 물을 첨가한 후 100℃에서 3시간 동안 열수 추출하여 제조된 추출물일 수 있으나, 이에 제한되지 않는다.In the composition for anti-obesity of the present invention, the thistle leaf extract may be an extract prepared by adding water to dried thistle leaves and then hot-extraction for 2 to 4 hours at 80 to 120 ° C, May be an extract prepared by adding water to dried thistle leaves and then hot-extraction at 100 ° C for 3 hours, but the present invention is not limited thereto.
본 발명에서의 용어, '항비만용 조성물'은 체중 감소, 내장 지방 감소, 혈중 중성지방 감소 또는 혈중 콜레스테롤 감소 중 하나 이상의 효과를 나타내는 조성물을 말하며, 상기 항비만용 조성물을 이용하여 비만 관련 질환, 즉 비만 및 비만으로부터 파생되는 당뇨병, 고지혈증, 심장병, 뇌졸증, 동맥경화증, 지방간 등의 각종 대사성 질환을 개선, 예방 또는 치료할 수 있으나, 이에 제한되지 않는다.The term " composition for anti-obesity " in the present invention refers to a composition exhibiting an effect of at least one of weight loss, visceral fat loss, blood triglyceride reduction or blood cholesterol reduction, Diabetes, hyperlipidemia, heart disease, stroke, arteriosclerosis, fatty liver, etc. derived from obesity and obesity, but the present invention is not limited thereto.
본 발명은 또한, 상기 조성물을 함유하는 비만 치료 또는 예방용 약학조성물을 제공한다. 본 발명의 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 포함할 수 있다.The present invention also provides a pharmaceutical composition for the treatment or prevention of obesity containing the above composition. The compositions of the present invention may comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.
본 발명의 조성물의 약학적 투여 형태는 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다.The pharmaceutical dosage forms of the compositions of the present invention may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable set.
본 발명에 따른 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함한 다양한 화합물 혹은 혼합물을 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 성분에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The composition according to the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., oral preparations, suppositories and sterilized injection solutions according to a conventional method have. Examples of carriers, excipients and diluents that may be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Various compounds or mixtures including cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명의 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 조성물은 1일 0.0001 내지 100 mg/kg으로, 바람직하게는 0.001 내지 100 mg/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the composition of the present invention is preferably administered at a daily dose of 0.0001 to 100 mg / kg, preferably 0.001 to 100 mg / kg. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.
본 발명의 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관내(intracerebroventricular) 주사에 의해 투여될 수 있다.The composition of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.
본 발명은 또한, 상기 조성물을 함유하는 비만 예방 또는 개선용 건강기능식품을 제공한다.The present invention also provides a health functional food for preventing or improving obesity containing the composition.
상기 건강기능식품은 비만을 예방 또는 개선시키기 위해 섭취할 수 있는 것이면 특별히 제한되지 않는다.The health functional food is not particularly limited as long as it can be ingested to prevent or improve obesity.
본 발명의 상기 조성물을 식품첨가물로 사용하는 경우, 상기 조성물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합양은 그의 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 조성물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.When the composition of the present invention is used as a food additive, the composition may be added as it is, or may be used together with other food or food ingredients, and suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). Generally, the composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight, based on the raw material, when the food or beverage is produced. However, in the case of long-term consumption intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range .
상기 식품의 종류에는 특별한 제한은 없다. 상기 조성물을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of foods to which the composition can be added include dairy products including meats, sausages, breads, chocolates, candies, snacks, confectionery, pizza, ramen noodles, gums, ice cream, soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include healthy foods in a conventional sense.
본 발명의 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.
상기 외에 본 발명의 건강음료 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강음료 조성물은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부당 0.01~0.1 중량부의 범위에서 선택되는 것이 일반적이다.
In addition to the above, the health beverage composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, Alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the health beverage composition of the present invention may contain flesh for the production of natural fruit juice, fruit juice beverage and vegetable beverage. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
이하, 본 발명의 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.
Hereinafter, embodiments of the present invention will be described in detail. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
제조예 1: 엉겅퀴 잎 열수 추출물의 제조Production Example 1: Preparation of hot-water extract of Thistle leaf
실험에 사용한 전라북도 임실군 오수면 소재 임실생약영농조합법인에서 재배한 엉겅퀴(Cirsium japonicum var. ussuriense) 잎은 채취하여 건조한 후, 건조된 상기 엉겅퀴 잎 200 g을 분말로 제조하여 증류수 3 L로 3시간 동안 추출기(100℃)로 열수 추출하였다. 상기 추출물은 0.45 ㎛ 필터를 사용하여 여과한 후 동결건조기(Eyela FDU-2100, Tokyo Rikakikai Co., Tokyo, Japan)에서 건조하여 48.9 g를 회수한 후 -20℃에서 보관하면서 실험에 사용하였다.
The leaf of Cirsium japonicum var. Ussuriense , cultivated in Damsil Agricultural Cooperative Incorporated in Ohsu-myeon, Jeollabuk-do, Jeollabuk-do, was harvested and dried. The dried thistle leaves (200 g) were prepared as powder, and extracted with 3 L of distilled water for 3 hours (100 < 0 > C). The extract was filtered using a 0.45 μm filter and dried in a freeze dryer (Eyela FDU-2100, Tokyo Rikakikai Co., Tokyo, Japan) to recover 48.9 g. The extract was stored at -20 ° C. and used in the experiment.
실험방법Experimental Method
가) 실험동물A) Experimental animals
무균환경에서 사육된 4주령의 C57BL/6J를 중앙실험동물(서울)로부터 구입하여 1주일의 순화기간을 거친 후 무작위로 군을 배정한 다음 실험에 사용하였다. 실험동물은 전 실험기간 동안 중앙실험동물에서 제공하는 일반 고형사료와 고지방사료(표 1)를 12주간 공급하고 물을 자유스럽게 섭취하도록 하였으며, 사육환경 온도 23±3℃, 밤낮주기(12시간)가 조절되는 환경에서 사육하였으며 전주대학교 실험동물위원회의 실험 규정에 준하여 실행하였다.Four weeks old C57BL / 6J grown in an aseptic environment was purchased from a central laboratory animal (Seoul) and subjected to a weekly purging period, randomly assigned to a group, and used in the experiment. The experimental animals were fed normal solid feed and high fat diets (Table 1) for 12 weeks and fed free of water during the whole experimental period. The feeding temperature was 23 ± 3 ℃, day and night cycle (12 hours) The experiment was carried out in accordance with the experiment regulations of the experimental animals committee of Jeonju University.
나) 혈액의 채취 및 혈중 지방 성분의 분석B) Blood sampling and blood lipid analysis
혈액은 실험이 종료되는 12주째 12시간 이상 절식시킨 후 마취하여 간문맥으로부터 채혈하였다. 채혈된 혈액은 4℃에서 충분히 방치한 후 10,000 rpm으로 10분 동안 원심분리하여 혈청을 얻어 총콜레스테롤, HDL-콜레스테롤, 중성지방을 상업용 키트(Asanpharm, Seoul, Korea)를 이용하여 측정하였다. LDL-콜레스테롤은 하기와 같은 식으로 계산하였다.Blood was collected from the portal vein by anesthesia after fasting for 12 hours at 12 weeks after the end of the experiment. Blood was collected and stored at 4 ° C, centrifuged at 10,000 rpm for 10 minutes, and serum was collected. Total cholesterol, HDL-cholesterol, and triglyceride were measured using a commercial kit (Asanpharm, Seoul, Korea). LDL-cholesterol was calculated by the following equation.
LDLc (mg/dl) = (TC - HDLc) - TG/5LDLc (mg / dl) = (TC - HDLc) - TG / 5
TC: 총 콜레스테롤 양, HDLc: HDL 콜레스테롤 양, TG: 중성지방 양
TC: total cholesterol level, HDLc: HDL cholesterol level, TG: triglyceride level
실시예 1: 엉겅퀴 추출물 투여에 따른 체형 및 내장지방 변화Example 1: Changes in body shape and visceral fat induced by administration of thistle extract
엉겅퀴 추출물 투여에 따른 12주 후 체형 및 내장지방 변화는 도 1 및 2와 같다. 도 1과 같이 엉겅퀴 추출물 투여군(CLE)은 100 mg/kg과 200 mg/kg에서 유의하게 변화의 양상이 뚜렷하였으며, 엉겅퀴 추출물 200 mg/kg 투여군에서는 참고약물인 아피게닌(20 mg/kg) 투여군과 유사하였다. 또한, 12주 후 내장지방 변화는 도 2와 같이 엉겅퀴 추출물 투여군은 100 mg/kg과 200 mg/kg에서 유의하게 변화의 양상이 뚜렷하였으며, 엉겅퀴 추출물 200 mg/kg 투여군에서는 참고약물인 아피게닌(20 mg/kg) 투여군과 유사하였다.
Body and visceral fat changes after 12 weeks of administration of thistle extract are shown in FIGS. 1 and 2. As shown in FIG. 1, there was a significant change in CLE between 100 mg / kg and 200 mg / kg. In the group administered with 200 mg / kg of thistle extract, apigenin (20 mg / kg) Respectively. As shown in FIG. 2, the visceral fat change after 12 weeks was significantly changed at 100 mg / kg and 200 mg / kg in the group administered with thistle extract, and in the group administered with 200 mg / kg of thistle extract, apigenin 20 mg / kg).
실시예 2: 엉겅퀴 추출물 투여에 따른 혈중 지방성분 변화Example 2: Changes in blood lipid composition upon administration of thistle extract
엉겅퀴 추출물 투여에 따른 12주 후 혈중 중성지방 함량의 변화는 도 3과 같이 엉겅퀴 추출물(CLE) 100 mg/kg 투여군에서는 큰 변화가 없었지만, 200 mg/kg 투여군에서는 유의하게 그 함량이 억제되었고 참고 약물인 아피게닌과 유사하였다. 또한, 엉겅퀴 추출물 투여에 따른 12주 후 혈중 콜레스테롤, HDL 및 LDL 함량의 변화는 도 4 내지 6과 같이 엉겅퀴 추출물 100 mg/kg 투여군에서는 큰 변화가 없었지만, 200 mg/kg 투여군에서는 유의하게 그 함량이 억제되었고 참고 약물인 아피게닌과 유사하였다.As shown in FIG. 3, the change in the blood triglyceride content after 12 weeks of administration of thistle extract was not significantly changed in the group administered with 100 mg / kg of thistle extract (CLE), but the content was significantly inhibited in the 200 mg / kg group, Like apigenin. In addition, the changes in blood cholesterol, HDL and LDL contents after 12 weeks of administration of thistle extract were not significantly changed in the group administered with 100 mg / kg of thistle extract as shown in FIGS. 4 to 6, And was similar to the reference drug apigenin.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140160646A KR20160059152A (en) | 2014-11-18 | 2014-11-18 | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140160646A KR20160059152A (en) | 2014-11-18 | 2014-11-18 | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160059152A true KR20160059152A (en) | 2016-05-26 |
Family
ID=56104577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140160646A KR20160059152A (en) | 2014-11-18 | 2014-11-18 | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160059152A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200125156A (en) | 2019-04-26 | 2020-11-04 | 한국식품연구원 | Composition for improvementing, preventing or treating obesity and metabolic diseases comprising fractions or extract of pepper leave |
| KR102251845B1 (en) * | 2020-12-23 | 2021-05-14 | 심재석 | Cultivation Method of Thistle Having High Content of Active Ingredient |
-
2014
- 2014-11-18 KR KR1020140160646A patent/KR20160059152A/en not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200125156A (en) | 2019-04-26 | 2020-11-04 | 한국식품연구원 | Composition for improvementing, preventing or treating obesity and metabolic diseases comprising fractions or extract of pepper leave |
| KR20210100069A (en) | 2019-04-26 | 2021-08-13 | 한국식품연구원 | Composition for improvementing, preventing or treating obesity and metabolic diseases comprising fractions or extract of pepper leave |
| KR102251845B1 (en) * | 2020-12-23 | 2021-05-14 | 심재석 | Cultivation Method of Thistle Having High Content of Active Ingredient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101691205B1 (en) | Composition comprising herbal extract for preventing or treating fatty liver disease | |
| KR101559130B1 (en) | Composition comprising herbal extract for preventing or treating obesity | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| KR102112599B1 (en) | Anti-obesity composition comprising Punica granatum and Citrus junos extract as effective component | |
| KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
| KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
| WO2005094858A1 (en) | Antidiabetic composition | |
| KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
| KR102470155B1 (en) | Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale | |
| KR102414431B1 (en) | A composition for improving, preventing and treating of diabetes mellitus | |
| KR101591460B1 (en) | Composition comprising mixture extract of Ephedra sinica, Rheum palmatum L and Arnebia euchroma for preventing or treating obesity | |
| KR20140032961A (en) | Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof | |
| KR20160139953A (en) | Anti-obesity composition comprising Cirsium japonicum flower extract as effective component | |
| KR101336068B1 (en) | Anti-diabetes composition comprising oriental herbal extracts and fractions | |
| KR20110121849A (en) | Composition for prevention or treatment of obesity or hyperlipedemia comprising the extracts of gymnaster koraiensis or artemisia dubia | |
| KR20160094313A (en) | Composition for anti-obesity comprising Chaenomelis Fructus extract or its fraction as effective component | |
| KR101181347B1 (en) | Composition for the prevention and treatment of lipid-related cardiovascular disease or obesity containing the extracts of Dictamnus dasycarpus as active ingredient | |
| KR100888068B1 (en) | Compositions for suppressing obesity | |
| KR101811210B1 (en) | Composition for treatment, improvement or prevention of Diabetes comprising extract of fruit of Sorbus commixta as an effective component | |
| KR100760386B1 (en) | Composition comprising the extract of ACP mixed crude drugs for preventing and treating arthritis | |
| KR101293032B1 (en) | Pharmaceutical composition for treating or preventing obesity comprising sea tangle and sodium butyrate as effective component | |
| WO2021112263A1 (en) | Adiponectin production promoter | |
| KR101904819B1 (en) | Composition comprising Fermented Momordica charantia L. and Allium sativum L. using Amyloliquefaciens Bacillus Jis-1 for lowering blood glucose or preventing and treating diabetes mellitus | |
| KR100686362B1 (en) | A composition comprising an extract of zizyphus jujuba mill. var. inermis rehder for treating and preventing obesity | |
| KR20170055366A (en) | A composition for preventing or treating obesity comprising taraxacum coreanum root extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |